MIMEDX GROUP, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.8 USD | -1.14% |
|
+4.70% | -11.06% |
| Apr. 30 | Transcript : MiMedx Group, Inc., Q1 2024 Earnings Call, Apr 30, 2024 | |
| Apr. 30 | Earnings Flash (MDXG) MIMEDX GROUP Posts Q1 Revenue $84.7M, vs. Street Est of $79.4M | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 361M | Sales 2025 * | 406M | Capitalization | 1.15B |
|---|---|---|---|---|---|
| Net income 2024 * | 45M | Net income 2025 * | 55M | EV / Sales 2024 * | 3.18 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.83 x |
| P/E ratio 2024 * |
24.9
x | P/E ratio 2025 * |
18.8
x | Employees | 895 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.64% |
More Fundamentals
* Assessed data
More news
Latest transcript on MiMedx Group, Inc.
More recommendations
More press releases
More news
| 1 day | -1.14% | ||
| 1 week | +4.70% | ||
| Current month | +26.62% | ||
| 1 month | +23.22% | ||
| 3 months | -3.23% | ||
| 6 months | +10.48% | ||
| Current year | -11.06% |
1 week
7.44
8.24
1 month
5.658.24
Current year
5.659.04
1 year
5.479.27
3 years
2.4315.99
5 years
2.4315.99
10 years
0.9518.25
| Managers | Title | Age | Since |
|---|---|---|---|
Joe Capper
CEO | Chief Executive Officer | 60 | 23-01-26 |
Douglas Rice
DFI | Director of Finance/CFO | 58 | 23-07-04 |
John R. Harper
CTO | Chief Tech/Sci/R&D Officer | - | 21-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
William Hawkins
BRD | Director/Board Member | 70 | 20-07-01 |
Phyllis Gardner
BRD | Director/Board Member | 73 | 21-03-07 |
K. Newton
BRD | Director/Board Member | 61 | 19-06-18 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.05% | 2 M€ | -.--% | ||
| 0.01% | 746 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-17 | 7.8 | -1.14% | 563,864 |
| 24-05-16 | 7.89 | -2.35% | 709,087 |
| 24-05-15 | 8.08 | +2.54% | 693,667 |
| 24-05-14 | 7.88 | -0.25% | 842,809 |
| 24-05-13 | 7.9 | +6.04% | 1,031,594 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotes
MiMedx Group, Inc. is a placental biologics company. The Company is engaged in developing and distributing placental tissue allografts with patent-protected, processes for multiple sectors of healthcare. Its product portfolio categories include Wound Care Products, and Surgical and Other Products. Its Wound Care Products include EPIFIX, EPICORD and EPIEFFECT, which are all marketed for external use, such as in advanced wound care applications. Its Surgical and Other product offering includes AMNIOFIX, AMNIOCORD and AMNIOEFFECT, which are positioned for use in a variety of applications and surgical settings, including lower extremity repair, plastic surgery, vascular surgery and multiple orthopedic repairs and reconstructions. The Company's platform technologies include tissue allografts derived from the human placental membrane, tissue allografts derived from the human umbilical cord, and a particulate extracellular matrix derived from the human placental disc.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
7.8
USD
Average target price
12.68
USD
Spread / Average Target
+62.61%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -11.06% | 1.15B | |
| -20.55% | 130M | |
| -0.78% | 72.61M | |
| +6.50% | 61.29M | |
| +1.12% | 55.32M | |
| -2.99% | 50.98M |
- Stock Market
- Equities
- MDXG Stock
